Suppr超能文献

癌前和恶性浆细胞疾病细胞外囊泡中蛋白质组的差异。

Differences in the proteome within extracellular vesicles between premalignant and malignant plasma cell disorders.

机构信息

Department of Laboratory Medicine and Pathology, Division of Clinical Biochemistry and Immunology, Mayo Clinic, Rochester, Minnesota, USA.

Department of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

出版信息

Eur J Haematol. 2024 Sep;113(3):351-356. doi: 10.1111/ejh.14246. Epub 2024 May 28.

Abstract

BACKGROUND

Precursor plasma cell disorders such as monoclonal gammopathy of undetermined significance (MGUS) always precede the development of active malignancies such as multiple myeloma (MM). There is a need for novel biomarkers to identify those patients with such precursor plasma cell disorders who rapidly progress to MM. Plasma-derived extracellular vesicles (EVs) may serve as a reservoir of potential biomarkers that can shed light on the pathogenesis and disease biology of MM.

METHODS

This study isolated small EVs (SEVs) and large EVs (LEVs) from the platelet-poor peripheral blood plasma of MGUS (n = 9) and MM (n = 12) patients using the size exclusion chromatography-based method and evaluated their proteome using a label-free proteomics workflow.

RESULTS

In total, 2055 proteins were identified in SEVs, while 2794 proteins were identified in LEVs. The transferrin receptor (or CD71) protein was upregulated in both populations of EVs derived from MM patients compared to MGUS patients and was of prognostic significance. Similarly, three isoforms of serum amyloid A (SAA) protein, SAA1, SAA2, and SAA4, were also highly upregulated in SEVs within MM patients relative to MGUS patients. Finally, CD40 expression was also higher in the LEVs derived from MM patients than in MGUS patients.

CONCLUSIONS

This study demonstrates the feasibility of successfully isolating both SEVs and LEVs from the peripheral blood of patients with plasma cell disorders and quantifying protein biomarkers within these EVs that could be of prognostic and diagnostic interest.

摘要

背景

前驱浆细胞疾病,如意义未明的单克隆丙种球蛋白血症(MGUS),总是先于多发性骨髓瘤(MM)等活动性恶性肿瘤的发展。需要新的生物标志物来识别那些前驱浆细胞疾病患者,这些患者会迅速进展为 MM。血浆来源的细胞外囊泡(EVs)可能是潜在生物标志物的储存库,这些标志物可以揭示 MM 的发病机制和疾病生物学。

方法

本研究使用基于排阻色谱的方法从小麦细胞浆细胞疾病(MGUS,n=9)和 MM(n=12)患者的血小板贫乏外周血浆中分离小 EVs(SEVs)和大 EVs(LEVs),并使用无标记蛋白质组学工作流程评估其蛋白质组。

结果

总共在 SEVs 中鉴定出 2055 种蛋白质,在 LEVs 中鉴定出 2794 种蛋白质。与 MGUS 患者相比,MM 患者的 EVs 中转铁蛋白受体(或 CD71)蛋白在两种 EV 群体中均上调,且具有预后意义。同样,三种血清淀粉样蛋白 A(SAA)蛋白同工型,SAA1、SAA2 和 SAA4,在 MM 患者的 SEVs 中也高度上调,而在 MGUS 患者中则下调。最后,CD40 的表达在 MM 患者的 LEVs 中也高于 MGUS 患者。

结论

本研究表明,成功地从小麦细胞浆细胞疾病患者的外周血中分离 SEVs 和 LEVs 并定量分析这些 EV 中的蛋白质生物标志物是可行的,这些生物标志物可能具有预后和诊断意义。

相似文献

1
Differences in the proteome within extracellular vesicles between premalignant and malignant plasma cell disorders.
Eur J Haematol. 2024 Sep;113(3):351-356. doi: 10.1111/ejh.14246. Epub 2024 May 28.
2
¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
Clin Exp Med. 2015 Feb;15(1):1-18. doi: 10.1007/s10238-014-0308-3. Epub 2014 Sep 14.
3
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma.
Cancer Biomark. 2025 Jun;42(6):18758592251344936. doi: 10.1177/18758592251344936. Epub 2025 Jun 9.
8
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
10
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.

本文引用的文献

1
A brief history of nearly EV-erything - The rise and rise of extracellular vesicles.
J Extracell Vesicles. 2021 Dec;10(14):e12144. doi: 10.1002/jev2.12144.
2
A size-exclusion-based approach for purifying extracellular vesicles from human plasma.
Cell Rep Methods. 2021 Jul 26;1(3). doi: 10.1016/j.crmeth.2021.100055.
4
Extracellular Vesicles in Hematological Malignancies: From Biomarkers to Therapeutic Tools.
Diagnostics (Basel). 2020 Dec 9;10(12):1065. doi: 10.3390/diagnostics10121065.
5
The emerging role of exosomes in multiple myeloma.
Blood Rev. 2019 Nov;38:100595. doi: 10.1016/j.blre.2019.100595. Epub 2019 Aug 8.
8
Pathogenesis beyond the cancer clone(s) in multiple myeloma.
Blood. 2015 May 14;125(20):3049-58. doi: 10.1182/blood-2014-11-568881. Epub 2015 Apr 2.
9
Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma.
Haematologica. 2015 Jun;100(6):834-841. doi: 10.3324/haematol.2014.118000. Epub 2015 Feb 24.
10
Multifunctional CD40L: pro- and anti-neoplastic activity.
Tumour Biol. 2014 Oct;35(10):9447-57. doi: 10.1007/s13277-014-2407-x. Epub 2014 Aug 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验